Your browser doesn't support javascript.
loading
Linkers in fragment-based drug design: an overview of the literature.
Grenier, Dylan; Audebert, Solène; Preto, Jordane; Guichou, Jean-François; Krimm, Isabelle.
Afiliação
  • Grenier D; Team Small Molecules for Biological Targets, Centre de Recherche En Cancérologie (CRCL) - INSERM 1052 - CNRS 5286 - Centre Léon Bérard - Université Claude Bernard Lyon 1, Institut Convergence Plascan, Lyon, France.
  • Audebert S; Centre de Biologie Structurale, CNRS, INSERM, Univ. Montpellier, Montpellier, France.
  • Preto J; Team Small Molecules for Biological Targets, Centre de Recherche En Cancérologie (CRCL) - INSERM 1052 - CNRS 5286 - Centre Léon Bérard - Université Claude Bernard Lyon 1, Institut Convergence Plascan, Lyon, France.
  • Guichou JF; Centre de Biologie Structurale, CNRS, INSERM, Univ. Montpellier, Montpellier, France.
  • Krimm I; Team Small Molecules for Biological Targets, Centre de Recherche En Cancérologie (CRCL) - INSERM 1052 - CNRS 5286 - Centre Léon Bérard - Université Claude Bernard Lyon 1, Institut Convergence Plascan, Lyon, France.
Expert Opin Drug Discov ; 18(9): 987-1009, 2023.
Article em En | MEDLINE | ID: mdl-37466331
ABSTRACT

INTRODUCTION:

In fragment-based drug design, fragment linking is a popular strategy where two fragments binding to different sub-pockets of a target are linked together. This attractive method remains challenging especially due to the design of ideal linkers. AREAS COVERED The authors review the types of linkers and chemical reactions commonly used to the synthesis of linkers, including those utilized in protein-templated fragment self-assembly, where fragments are directly linked in the presence of the protein. Finally, they detail computational workflows and software including generative models that have been developed for fragment linking. EXPERT OPINION The authors believe that fragment linking offers key advantages for compound design, particularly for the design of bivalent inhibitors linking two distinct pockets of the same or different subunits. On the other hand, more studies are needed to increase the potential of protein-templated approaches in FBDD. Important computational tools such as structure-based de novo software are emerging to select suitable linkers. Fragment linking will undoubtedly benefit from developments in computational approaches and machine learning models.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Software / Desenho de Fármacos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Software / Desenho de Fármacos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article